Trials / Completed
CompletedNCT03204786
Intranasal Vasopressin Treatment in Children With Autism
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 157 (actual)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 6 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical trial is to investigate the effectiveness of vasopressin nasal spray for treating symptoms associated with autism. Vasopressin is a hormone that is produced naturally within the body and has been implicated in regulating social behaviors. It has been proposed that administration of the hormone may also help improve social functioning in individuals with autism.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vasopressin (USP) Injectable Solution [Vasostrict] | Nasal Spray |
| DRUG | Placebo | Placebo Nasal Spray |
Timeline
- Start date
- 2018-02-20
- Primary completion
- 2024-03-18
- Completion
- 2024-03-18
- First posted
- 2017-07-02
- Last updated
- 2025-09-19
- Results posted
- 2025-09-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03204786. Inclusion in this directory is not an endorsement.